Clinical Trial

Retifanlimab and Ruxolitinib In Solid Malignancies

Study acronym: PRISM
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma. The main question it aims to answer is: What is the maximum dose of ruxolitinib that can be used safely in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma, and will it work? Participants will: Take drug ruxolitinib twice a day and keep a diary of when they take ruxolitinib at home; visit the clinic for infusions of retifanlimab every 4 weeks; visit the clinic for checkups and tests.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-20.
Status change: Not Yet Recruiting → Recruiting 2026-01-10
Trial Details
NCT Number NCT07219576
Lead Sponsor University of California, San Diego
Collaborators: Incyte Corporation
Conditions Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
Enrollment 40 participants
Start Date 2026-01-08
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-13